{"id":7176,"date":"2025-04-26T17:03:26","date_gmt":"2025-04-26T22:03:26","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=6023"},"modified":"2025-07-13T15:09:30","modified_gmt":"2025-07-13T20:09:30","slug":"nanoscope-participation-at-eyecelerator-and-arvo-2025","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ar\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","title":{"rendered":"\u0623\u0639\u0644\u0646\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0639\u0646 \u0645\u0634\u0627\u0631\u0643\u062a\u0647\u0627 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639\u064a\u0646 \u0627\u0644\u0633\u0646\u0648\u064a\u064a\u0646 \u0644\u0640 Eyecelerator\u00ae \u0648 ARVO \u0644\u0639\u0627\u0645 2025"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h3 class=\"prntac\" style=\"text-align: center;\"><em>Presentations to highlight efficacy, durability, and safety of\u00a0Nanoscope&#8217;s optogenetic therapy platforms<\/em><\/h3>\n<\/div>\n<div class=\"col-sm-4 col-xs-12 col-vcenter\">\n<div class=\"image logo logo-wrapper\" data-src=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-asset-type=\"photo\" data-asset-label=\"Logo\" data-download-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg\" data-tweet-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-pinterest-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-linkedin-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-facebook-share-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-twitter-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=twitter\" data-facebook-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=facebook\" data-pinterest-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-linkedin-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=linkedin\">\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">\u062f\u0627\u0644\u0627\u0633<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">25 \u0623\u0628\u0631\u064a\u0644 2025<\/span><\/span>\u00a0 \u2014 <a href=\"http:\/\/nanostherapeutics.com\/ar\/\" target=\"_blank\" rel=\"nofollow noopener\">\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u0644\u0644\u0639\u0644\u0627\u062c\u0627\u062a<\/a>, \u0623\u0639\u0644\u0646\u062a \u0634\u0631\u0643\u0629 \u0627\u0644\u062a\u0643\u0646\u0648\u0644\u0648\u062c\u064a\u0627 \u0627\u0644\u062d\u064a\u0648\u064a\u0629\u060c \u0627\u0644\u0645\u0644\u062a\u0632\u0645\u0629 \u0628\u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u062f\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0645\u0643\u0641\u0648\u0641\u064a\u0646 \u0641\u064a \u0628\u064a\u0626\u0627\u062a \u0648\u0627\u0642\u0639\u064a\u0629 \u0645\u0646 \u062e\u0644\u0627\u0644 \u062a\u0637\u0648\u064a\u0631 \u0648\u062a\u0633\u0648\u064a\u0642 \u0639\u0644\u0627\u062c\u0627\u062a \u062c\u064a\u0646\u064a\u0629 \u0645\u0628\u062a\u0643\u0631\u0629 \u0644\u0623\u0645\u0631\u0627\u0636 \u062a\u0646\u0643\u0633 \u0627\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0627\u0644\u064a\u0648\u0645 \u0639\u0646 \u0645\u0634\u0627\u0631\u0643\u062a\u0647\u0627 \u0641\u064a \u0643\u0644 \u0645\u0646\u00a0<a href=\"https:\/\/www.eyecelerator.com\/\" target=\"_blank\" rel=\"nofollow noopener\">\u0645\u064f\u0633\u0631\u0639 \u0627\u0644\u0639\u064a\u0646<\/a>\u00a0\u0648\u00a0<a href=\"https:\/\/www.arvo.org\/annual-meeting\/\" target=\"_blank\" rel=\"nofollow noopener\">\u062c\u0645\u0639\u064a\u0629 \u0623\u0628\u062d\u0627\u062b \u0627\u0644\u0631\u0624\u064a\u0629 \u0641\u064a \u0637\u0628 \u0627\u0644\u0639\u064a\u0648\u0646 (ARVO) 2025<\/a>\u00a0annual meetings. Nanoscope&#8217;s presentations will be centered around 126-week outcomes following treatment with its\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ar\/technology-2\/\" target=\"_blank\" rel=\"nofollow noopener\">\u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0628\u0635\u0631\u064a \u0627\u0644\u0648\u0631\u0627\u062b\u064a MCO-010<\/a>\u00a0\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP)\u060c \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0623\u0648\u0644 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u00a0<a href=\"https:\/\/www.cell.com\/molecular-therapy-family\/molecular-therapy\/fulltext\/S1525-0016(25)00205-9\" target=\"_blank\" rel=\"nofollow noopener\">\u062b\u0628\u062a \u0623\u0646\u0647\u0627 \u062a\u0639\u064a\u062f \u0627\u0644\u0628\u0635\u0631 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a \u0627\u0644\u0645\u062a\u0642\u062f\u0645<\/a>\u00a0\u0639\u0646 \u0637\u0631\u064a\u0642 \u062d\u0642\u0646\u0629 \u0648\u0627\u062d\u062f\u0629 \u0642\u064a\u0627\u0633\u064a\u0629 \u062f\u0627\u062e\u0644 \u0627\u0644\u062c\u0633\u0645 \u0627\u0644\u0632\u062c\u0627\u062c\u064a.<\/p>\n<p>&#8220;We are excited to have such a substantial presence at both the Eyecelerator and ARVO annual meetings and look forward to sharing more about the positive therapeutic benefits seen in RP patients treated with our multi-characteristic opsin, or MCO, therapy,&#8221; said Dr.\u00a0<span class=\"xn-person\">\u0633\u0627\u0645\u0627\u0631\u0646\u062f\u0631\u0627 \u0645\u0648\u0647\u0627\u0646\u062a\u064a<\/span>, co-founder and President of Nanoscope. &#8220;Multi-year benefit is meaningful for patients looking for a one-time, durable treatment option for their irreversible, progressive vision loss due to RP, and it underscores the potential of MCO-010 to redefine the standard of care. It is an exciting time at Nanoscope as we prepare MCO-010 for commercialization, including BLA submission.&#8221;<\/p>\n<p>\u062a\u0641\u0627\u0635\u064a\u0644 \u0627\u0644\u0639\u0631\u0648\u0636 \u0627\u0644\u062a\u0642\u062f\u064a\u0645\u064a\u0629 \u0643\u0627\u0644\u062a\u0627\u0644\u064a:<\/p>\n<p><b><a href=\"https:\/\/www.eyecelerator.com\/\" target=\"_blank\" rel=\"nofollow noopener\">\u0645\u064f\u0633\u0631\u0639 \u0627\u0644\u0639\u064a\u0646\u00a0<\/a><\/b><br class=\"dnr\" \/><span class=\"xn-chron\">\u0627\u0644\u062c\u0645\u0639\u0629\u060c 2 \u0645\u0627\u064a\u0648<\/span><sup>\u0627\u062e\u062a\u0635\u0627\u0631 \u0627\u0644\u062b\u0627\u0646\u064a<\/sup>, 2025<br class=\"dnr\" \/>\u062c\u0631\u0627\u0646\u062f\u00a0<span class=\"xn-person\">\u0641\u0646\u062f\u0642 \u062d\u064a\u0627\u0629 \u062f\u064a\u0631 \u0641\u0627\u0644\u064a<\/span>,\u00a0<span class=\"xn-location\">\u0628\u0627\u0631\u0643 \u0633\u064a\u062a\u064a\u060c \u064a\u0648\u062a\u0627<\/span><\/p>\n<p>\u0645\u0634\u0627\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628:<\/p>\n<ul type=\"disc\">\n<li><b>12:30 \u2013 1:30 \u0645\u0633\u0627\u0621\u064b \u0628\u062a\u0648\u0642\u064a\u062a \u0627\u0644\u062c\u0628\u0627\u0644\u00a0<\/b>\u2013 \u062c\u0644\u0633\u0629 \u0646\u0642\u0627\u0634 \u2013 \u0633\u0623\u064f\u0637\u0644\u0642 \u0633\u0631\u0627\u062d\u064a: \u0623\u0633\u0627\u0644\u064a\u0628 \u062c\u062f\u064a\u062f\u0629 \u0644\u0625\u064a\u0635\u0627\u0644 \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u0644\u0648\u0643\u0648\u0645\u0627 \u0648\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0639\u064a\u0646 \u2013 \u062f.\u00a0<span class=\"xn-person\">\u0633\u0627\u0645 \u0628\u0627\u0631\u0648\u0646<\/span>, \u0643\u0628\u064a\u0631 \u0627\u0644\u0645\u0633\u0624\u0648\u0644\u064a\u0646 \u0627\u0644\u0637\u0628\u064a\u064a\u0646<br class=\"dnr\" \/><br class=\"dnr\" \/><\/li>\n<li><b>1:59 \u2013 2:04 \u0645\u0633\u0627\u0621\u064b \u0628\u062a\u0648\u0642\u064a\u062a MDT\u061b \u0642\u0627\u0639\u0629 \u0633\u062a\u0631\u0648\u0628\u064a\u0631\u064a\u00a0<\/b>\u2013 \u0639\u0631\u0648\u0636 \u0627\u0644\u0634\u0631\u0643\u0627\u062a \u0627\u0644\u0645\u0642\u062f\u0645\u0629: \u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0639\u064a\u0646: \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u064a\u0646\u064a \u0648\u0622\u0644\u064a\u0627\u062a \u0627\u0644\u0639\u0645\u0644 \u0627\u0644\u062c\u062f\u064a\u062f\u0629 \u2013 \u062f.\u00a0<span class=\"xn-person\">\u062c\u0627\u0631\u064a\u062f \u0633\u062a\u064a\u0641\u0646\u0632<\/span>, \u0646\u0627\u0626\u0628 \u0627\u0644\u0631\u0626\u064a\u0633 \u0644\u0644\u0627\u0633\u062a\u0631\u0627\u062a\u064a\u062c\u064a\u0629 \u0648\u062a\u0637\u0648\u064a\u0631 \u0627\u0644\u0623\u0639\u0645\u0627\u0644<br class=\"dnr\" \/><br class=\"dnr\" \/><\/li>\n<li><b>3:30 \u2013\u00a0<span class=\"xn-chron\">4:15 \u0645\u0633\u0627\u0621\u064b<\/span><\/b>\u00a0<b>\u0625\u0645 \u062f\u064a \u062a\u064a<\/b>\u00a0\u2013 \u062d\u0644\u0642\u0629 \u0646\u0642\u0627\u0634 \u2013 \u0628\u0644\u0627 \u0648\u062c\u0647\u0629 \u0645\u062d\u062f\u062f\u0629: \u0625\u0631\u0634\u0627\u062f\u0627\u062a \u0644\u0644\u062a\u0646\u0642\u0644 \u0641\u064a \u0627\u0644\u0645\u0633\u0627\u0631\u0627\u062a \u0627\u0644\u062a\u0646\u0638\u064a\u0645\u064a\u0629 \u0627\u0644\u0645\u0639\u0642\u062f\u0629 \u0628\u0634\u0643\u0644 \u0645\u062a\u0632\u0627\u064a\u062f \u2013 \u062f.\u00a0<span class=\"xn-person\">\u0633\u0627\u0645 \u0628\u0627\u0631\u0648\u0646<\/span><\/li>\n<\/ul>\n<p><b><a href=\"https:\/\/www.arvo.org\/annual-meeting\/\" target=\"_blank\" rel=\"nofollow noopener\">ARVO\u060c \u062c\u0645\u0639\u064a\u0629 \u0623\u0628\u062d\u0627\u062b \u0627\u0644\u0631\u0624\u064a\u0629 \u0648\u0637\u0628 \u0627\u0644\u0639\u064a\u0648\u0646<\/a><br class=\"dnr\" \/><\/b><span class=\"xn-chron\">\u0627\u0644\u0623\u062d\u062f\u060c 4 \u0645\u0627\u064a\u0648<\/span><sup>\u0630<\/sup>\u00a0\u0644\u00a0<span class=\"xn-chron\">\u0627\u0644\u062e\u0645\u064a\u0633\u060c 8 \u0645\u0627\u064a\u0648<\/span><sup>\u0630<\/sup>, 2025<br class=\"dnr\" \/>\u0645\u0631\u0643\u0632 \u0645\u0624\u062a\u0645\u0631\u0627\u062a \u0642\u0635\u0631 \u0627\u0644\u0645\u0644\u062d\u060c,\u00a0<span class=\"xn-location\">\u0645\u062f\u064a\u0646\u0629 \u0633\u0648\u0644\u062a \u0644\u064a\u0643\u060c \u064a\u0648\u062a\u0627<\/span><\/p>\n<p>\u0639\u0631\u0648\u0636 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628:<\/p>\n<ul type=\"disc\">\n<li><b><span class=\"xn-chron\">\u0627\u0644\u0623\u062d\u062f\u060c 4 \u0645\u0627\u064a\u0648<\/span><sup>\u0630<\/sup>, 1:30 \u2013\u00a0<span class=\"xn-chron\">1:45 \u0645\u0633\u0627\u0621\u064b \u0628\u062a\u0648\u0642\u064a\u062a \u0627\u0644\u062c\u0628\u0627\u0644<\/span>; \u0642\u0627\u0639\u0629 \u0627\u0644\u0631\u0642\u0635 G\u00a0<\/b>- \u0622\u0646\u0633\u0629.\u00a0<span class=\"xn-person\">\u0644\u0648\u0633\u064a\u0631\u0648 \u063a\u0627\u0631\u0633\u064a\u0627<\/span>\u00a0presenting \u2013 &#8220;Multi-characteristic opsin gene therapy attenuates retinal degeneration and restores vision in NHP model of geographic atrophy&#8221;<br class=\"dnr\" \/><br class=\"dnr\" \/><\/li>\n<li><b><span class=\"xn-chron\">\u0627\u0644\u062b\u0644\u0627\u062b\u0627\u0621\u060c 6 \u0645\u0627\u064a\u0648<\/span><sup>\u0630<\/sup>, 9:15 \u2013\u00a0<span class=\"xn-chron\">9:30 \u0635\u0628\u0627\u062d\u064b\u0627 \u0628\u062a\u0648\u0642\u064a\u062a \u0627\u0644\u062c\u0628\u0627\u0644<\/span>; \u0642\u0627\u0639\u0629 \u0627\u0644\u0631\u0642\u0635 \u0628\u00a0<\/b>\u2013 Dr. SriniVas Sadda presenting \u2013 &#8220;126-Week Visual Acuity Outcomes Following Mutation-Agnostic Optogenetic Therapy, MCO-010, for Retinitis Pigmentosa (RP)&#8221;<br class=\"dnr\" \/><br class=\"dnr\" \/><\/li>\n<li><b><span class=\"xn-chron\">\u0627\u0644\u062e\u0645\u064a\u0633\u060c 8 \u0645\u0627\u064a\u0648<\/span><sup>\u0630<\/sup>, \u0662:\u0664\u0665 \u2013\u00a0<span class=\"xn-chron\">\u0627\u0644\u0633\u0627\u0639\u0629 3:00 \u0645\u0633\u0627\u0621\u064b \u0628\u062a\u0648\u0642\u064a\u062a \u0627\u0644\u062c\u0628\u0627\u0644<\/span>; \u0642\u0627\u0639\u0629 \u0627\u0644\u0631\u0642\u0635 F\u00a0<\/b>- \u062f\u0643\u062a\u0648\u0631.\u00a0<span class=\"xn-person\">\u0646\u0627\u062c \u0634\u0631\u064a\u0641<\/span>\u00a0presenting \u2013 &#8220;Safety and Efficacy of an Image-Guided Laser-based Non-Viral Targeted Delivery of Multi-Characteristic Opsin Plasmids in African Green Monkey Retinae&#8221;<\/li>\n<\/ul>\n<p>\u0633\u064a\u0643\u0648\u0646 \u0623\u0639\u0636\u0627\u0621 \u0641\u0631\u064a\u0642 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u0645\u062a\u0648\u0627\u062c\u062f\u064a\u0646 \u0641\u064a \u0627\u0644\u062c\u0646\u0627\u062d \u0631\u0642\u0645 1337 \u0637\u0648\u0627\u0644 \u0641\u062a\u0631\u0629 \u0645\u0624\u062a\u0645\u0631 ARVO.<\/p>\n<p><b>\u062d\u0648\u0644 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u064a\u0643\u0633 \u0625\u0646\u0643.<br class=\"dnr\" \/><\/b>\u062a\u064f\u0637\u0648\u0651\u0631 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0639\u0644\u0627\u062c\u0627\u062a \u0628\u0635\u0631\u064a\u0629 \u0648\u0631\u0627\u062b\u064a\u0629 \u0644\u0627 \u062a\u062a\u0623\u062b\u0631 \u0628\u0627\u0644\u0637\u0641\u0631\u0627\u062a\u060c \u0648\u062a\u064f\u0639\u064a\u062f \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0644\u0627\u064a\u064a\u0646 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u0641\u0642\u062f\u0648\u0627 \u0628\u0635\u0631\u0647\u0645 \u0628\u0633\u0628\u0628 \u0623\u0645\u0631\u0627\u0636 \u062a\u0646\u0643\u0633\u064a\u0629 \u0641\u064a \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0644\u0627 \u064a\u0648\u062c\u062f \u0644\u0647\u0627 \u0639\u0644\u0627\u062c \u062d\u0627\u0644\u064a\u064b\u0627. \u0628\u0639\u062f \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0625\u064a\u062c\u0627\u0628\u064a\u0629 \u0641\u064a \u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u062f\u0631\u0627\u0633\u0629 \u0645\u0646 \u062a\u062c\u0631\u0628\u0629 \u0631\u064a\u0633\u062a\u0648\u0631 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u0645\u0631\u0627\u0643\u0632\u060c \u0627\u0644\u0639\u0634\u0648\u0627\u0626\u064a\u0629\u060c \u0645\u0632\u062f\u0648\u062c\u0629 \u0627\u0644\u062a\u0639\u0645\u064a\u0629\u060c \u0627\u0644\u0645\u064f\u062d\u0643\u0645\u0629 \u0628\u0634\u0643\u0644 \u0648\u0647\u0645\u064a\u060c \u0627\u0644\u0645\u0631\u062d\u0644\u0629 2\u0628\u060c \u0644\u0639\u0644\u0627\u062c \u0627\u0639\u062a\u0644\u0627\u0644 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>)\u060c \u0623\u0639\u0644\u0646\u062a \u0627\u0644\u0634\u0631\u0643\u0629 \u0639\u0646 \u062e\u0637\u062a\u0647\u0627 \u0644\u0628\u062f\u0621\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ar\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/\" target=\"_blank\" rel=\"nofollow noopener\">\u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628 \u062a\u0631\u062e\u064a\u0635 BLA \u0644\u0640 MCO-010 \u0644\u0639\u0644\u0627\u062c RP<\/a>\u00a0\u0641\u064a \u0627\u0644\u0646\u0635\u0641 \u0627\u0644\u0623\u0648\u0644 \u0645\u0646 \u0639\u0627\u0645 2025. \u0623\u0643\u0645\u0644\u062a \u0627\u0644\u0634\u0631\u0643\u0629 \u062a\u062c\u0631\u0628\u0629 STARLIGHT \u0644\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u0639\u0644\u0627\u062c MCO-010 \u0641\u064a \u0645\u0631\u0636\u0649 Stargardt (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) \u0648\u062a\u062e\u0637\u0637 \u0644\u0628\u062f\u0621\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ar\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">\u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u062a\u0633\u062c\u064a\u0644\u064a\u0629<\/a>, \u0623\u064a\u0636\u064b\u0627 \u0641\u064a \u0639\u0627\u0645 2025. \u062d\u0635\u0644 MCO-010 \u0639\u0644\u0649 \u062a\u0635\u0646\u064a\u0641\u0627\u062a \u0627\u0644\u0645\u0633\u0627\u0631 \u0627\u0644\u0633\u0631\u064a\u0639 \u0645\u0646 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0648\u062a\u0635\u0646\u064a\u0641\u0627\u062a \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u064a\u062a\u064a\u0645\u0629 \u0644\u0643\u0644 \u0645\u0646 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a \u0648\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a. \u062a\u0634\u0645\u0644 \u0627\u0644\u0628\u0631\u0627\u0645\u062c \u0645\u0627 \u0642\u0628\u0644 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u062f\u0648\u0627\u0621 MCO-020 \u063a\u064a\u0631 \u0627\u0644\u0641\u064a\u0631\u0648\u0633\u064a \u0627\u0644\u0630\u064a \u064a\u062a\u0645 \u062a\u0648\u0635\u064a\u0644\u0647 \u0628\u0627\u0644\u0644\u064a\u0632\u0631 \u0648\u0627\u0644\u0645\u062c\u0647\u0632 \u0644\u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628 \u062f\u0648\u0627\u0621 \u062c\u062f\u064a\u062f \u0644\u0639\u0644\u0627\u062c \u0636\u0645\u0648\u0631 \u0627\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0628\u0627\u0644\u0625\u0636\u0627\u0641\u0629 \u0625\u0644\u0649 \u062f\u0648\u0627\u0621 AAV \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0639\u0645\u0649 \u0627\u0644\u062e\u0644\u0642\u064a \u0644\u0644\u064a\u0628\u0631\u060c \u0648\u0627\u0644\u0630\u064a \u064a\u062e\u0636\u0639 \u062d\u0627\u0644\u064a\u064b\u0627 \u0644\u062f\u0631\u0627\u0633\u0627\u062a \u062a\u0645\u0647\u064a\u062f\u064a\u0629 \u0644\u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628 \u062f\u0648\u0627\u0621 \u062c\u062f\u064a\u062f.<\/p>\n<p><b>\u0627\u0644\u0627\u062a\u0635\u0627\u0644 \u0628\u0627\u0644\u0645\u0633\u062a\u062b\u0645\u0631:<\/b><br class=\"dnr\" \/>\u0634\u0631\u0643\u0627\u0621 \u0623\u0631\u063a\u0648\u062a<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<p>\u0627\u0644\u0645\u0635\u062f\u0631 \u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Presentations to highlight efficacy, durability, and safety of\u00a0Nanoscope&#8217;s optogenetic therapy platforms DALLAS,\u00a0April 25, 2025\u00a0 &#8212; Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced participation at both the\u00a0Eyecelerator\u00a0and\u00a0The Association for Research and Vision in Ophthalmology [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":7179,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-7176","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ar\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ar\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-26T22:03:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-13T20:09:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_MOLECULARTHERAPY_V1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_MOLECULARTHERAPY_V1.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 \u062f\u0642\u0627\u0626\u0642\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings\",\"datePublished\":\"2025-04-26T22:03:26+00:00\",\"dateModified\":\"2025-07-13T20:09:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\"},\"wordCount\":555,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_ARVO_LI_2025-.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ar\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\",\"name\":\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_ARVO_LI_2025-.jpg\",\"datePublished\":\"2025-04-26T22:03:26+00:00\",\"dateModified\":\"2025-07-13T20:09:30+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_ARVO_LI_2025-.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_ARVO_LI_2025-.jpg\",\"width\":1000,\"height\":1000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u0623\u0639\u0644\u0646\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0639\u0646 \u0645\u0634\u0627\u0631\u0643\u062a\u0647\u0627 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639\u064a\u0646 \u0627\u0644\u0633\u0646\u0648\u064a\u064a\u0646 \u0644\u0640 Eyecelerator\u00ae \u0648 ARVO \u0644\u0639\u0627\u0645 2025 - \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ar\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","og_locale":"ar_AR","og_type":"article","og_title":"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ar\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-04-26T22:03:26+00:00","article_modified_time":"2025-07-13T20:09:30+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_MOLECULARTHERAPY_V1.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_MOLECULARTHERAPY_V1.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629":"Nanoscope Therapeutics","\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"3 \u062f\u0642\u0627\u0626\u0642"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings","datePublished":"2025-04-26T22:03:26+00:00","dateModified":"2025-07-13T20:09:30+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/"},"wordCount":555,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_ARVO_LI_2025-.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ar"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","url":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","name":"\u0623\u0639\u0644\u0646\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0639\u0646 \u0645\u0634\u0627\u0631\u0643\u062a\u0647\u0627 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639\u064a\u0646 \u0627\u0644\u0633\u0646\u0648\u064a\u064a\u0646 \u0644\u0640 Eyecelerator\u00ae \u0648 ARVO \u0644\u0639\u0627\u0645 2025 - \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_ARVO_LI_2025-.jpg","datePublished":"2025-04-26T22:03:26+00:00","dateModified":"2025-07-13T20:09:30+00:00","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_ARVO_LI_2025-.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_ARVO_LI_2025-.jpg","width":1000,"height":1000},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628","description":"\u0625\u0639\u0627\u062f\u0629 \u0646\u0648\u0631 \u0627\u0644\u0623\u0645\u0644","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/7176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/comments?post=7176"}],"version-history":[{"count":3,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/7176\/revisions"}],"predecessor-version":[{"id":7213,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/7176\/revisions\/7213"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media\/7179"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media?parent=7176"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/categories?post=7176"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/tags?post=7176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}